To manage the behavior of the children with high levels of dental anxiety, the combination of inhalation sedation with intranasal midazolam can be efficiently used.
S-ketamine provides superior analgesia and reduces intraoperative opioid requirements without compromising sedation or anxiolysis, suggesting it may be a preferable option in this population of children undergoing tonsillectomy.
Ivana Fajertag, Vlado Janković, Maja Sujica et al.· Serbian Journal of Anesthesi...· 0 citations
The ED50 provides a preliminary reference for initial dose selection in this clinical setting and requires validation in larger studies, but the wide confidence interval of the ED95 limits its clinical utility and requires validation in larger studies.
Mengjiao Che, Cuiyao Kang, Cuiyun Zhou et al.· BMC Anesthesiology· 0 citations
Intranasal DEX at a dose of 1.5 mcg/kg is safe and effective premedication for paediatric patients, which results in successful sedation with tolerated changes in vitals, which was well tolerated.
Mona Sharma, Swagat Gongal, B. Yadav et al.· Journal of Nepal Health Rese...· 0 citations
Intranasal dexmedetomidine appears to be the preferred premedication for facilitating smooth anesthetic induction in pediatric patients undergoing elective surgery while maintaining comparable hemodynamic stability and induction time.
Arifa Sultan, Saeedah Asaf· Aposta: Revista de Ciencias...· 0 citations
OBJECTIVES
To compare the clinical efficacy of oral montelukast versus intranasal fluticasone furoate in reducing the severity of sleep-disordered breathing (SDB) among children with adenotonsillar hypertrophy.
METHODS
A prospective randomized clinical trial was conducted between 9/2022 and 4/2023, including children aged 2-15 years with SDB and adenotonsillar hypertrophy. At baseline, all participants underwent symptom assessment using the Pediatric Sleep Questionnaire (PSQ), followed by physical examination. Subjects were randomized to receive either oral montelukast or intranasal fluticasone furoate for two months. Following treatment, the children were re-evaluated, and if no clinical improvement was observed, surgery was scheduled.
RESULTS
Sixty-seven children with a mean age of 5.25 years (45, 67% males) were included. The median PSQ score improved in the montelukast group from 0.45 to 0.28 (p = 0.003) and in the fluticasone furoate group from 0.43 to 0.36 (p = 0.006) with comparable efficacy (p = 0.292). The prevalence of moderate-to-severe sleep apnea decreased from 67% to 41% with montelukast (p = 0.035) and from 81% to 60% with fluticasone furoate (p = 0.016). While both medications significantly reduced adenoid size (p < 0.001 and p < 0.001, respectively), only montelukast significantly reduced tonsillar size (p = 0.008).
CONCLUSIONS
Both montelukast and fluticasone furoate reduced the pediatric SDB severity. While both medications significantly decreased adenoid size, only montelukast significantly decreased tonsillar size. Therefore, fluticasone furoate may be appropriate for adenoid hypertrophy, while montelukast is favored for concurrent tonsillar hypertrophy. These treatments may serve as alternatives to surgery in selected cases. Further studies are needed to evaluate their long-term efficacy.
S. Rothman, Ronly Har-Even, Ofer Israel et al.· International Journal of Ped...· 0 citations
Findings indicate that administration through the nares dexmedetomidine at 0.06 or 0.08 mg/kg combined with midazolam and butorphanol provides deeper, more stable, and reversible sedation and improved control of stress responses in cockatiels and may represent a clinically useful protocol in this species.
Sakura Isayama, Mizuki Tanahashi, Seiko Doi et al.· Journal of Veterinary Medica...· 0 citations
